This is a normal physiological response to significant caloric and weight changes, not a sign that something is wrong
Proc Natl Acad Sci U S A 87:334347, PMID: 1970635 Messina JP, Lawrence DA (1989) Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase
Improved muscle tone
~33.3% of users lost 10% or more body weight ~9.5% of users lost 15% or more body weight Common side effects Side effects include but are not limited to nausea, heartburn, hypoglycemia, constipation, and diarrhea, among others
The company's next-gen weight-loss medicine, CagriSema, failed to meet management's projected 25% mean weight loss in a phase 3 study and proved inferior to Zepbound in a head-to-head trial
Read the full article here: Photo credit: The Straits Times #NUS #NUSPublicHealth #PublicHealth #SSHSPH #Health To view or add a comment, sign in Addressing solubility challenges leads to a greater flexibility in dosage forms and consistent therapeutic outcomes
